3io Therapeutics is a Toronto-based biotechnology company focused on the development and commercialisation of the next generation of viral immunotherapies for cancer.
3io is currently developing a novel viral immunotherapy based on bovine herpesvirus type 1 (BHV-1), a virus that naturally infects cattle but is non-pathogenic in humans. 3io is committed to accelerating its development as a new therapeutic platform to improve treatment responses and outcomes for hard-to-treat cancers, including those with KRAS-mutations.
Company Details
- Employees
- 3
- Founded
- 2020
- Address
- 100 King Street West, Suite 5700,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.3iotherapeutics.com/
- Keywords
- Oncology, Biotechnology, Immunotherapy.
- HQ
- Toronto, Ontario
3io Therapeutics Questions
3Io Therapeutics's website is https://www.3iotherapeutics.com/
3Io Therapeutics's LinkedIn profile is https://ca.linkedin.com/company/3io-therapeutics
3Io Therapeutics has
3 employees.
View email and phone details for 3
employees at 3Io Therapeutics.
3Io Therapeutics's industry is
Biotechnology Research
3Io Therapeutics's top competitors are
Vanqua Bio,
Innate Pharma,
Oak Hill Bio,
Ksq Therapeutics, Inc.,
Judo Bio,
Abalos Therapeutics Gmbh,
Clarity Pharmaceuticals,
Calluna Pharma,
Opthea,
Tract Therapeutics, Inc..
3Io Therapeutics's categories are Biotechnology Research
3Io Therapeutics's founding year is 2020
